,i  #aae? ,,congress  #b;d ,session  ,h4
 ,r4 #eiad  ,,9 ,,! ,,h\se ,,(          
,,repres5tatives  ,may #bb1 #bjah,mr4   
,mead[s introduc$ ! foll[+ bill2 :i* 0  
ref]r$ to ! ,committee on ,en]gy &      
,comm]ce  ,a ,,bill  ,to require a /udy 
& report on policy & regulatory *anges t
 may h contribut$ to ! opioid epidemic4 
#a4 ,,gao /udy & report on policy *anges
 t may h contribut$ to ! opioid epidemic
 ,n lat] ?an #b ye>s aft] ! date (      
enactm5t ( ?is ,act1 ! ,comptroll]      
,g5]al ( ! ,unit$ ,/ates %all complete a
 /udy & submit a report to ,congress on 
heal? c>e policy *anges t may h         
contribut$ to ! increase 9 opioid       
ov]doses & dea?s dur+ ! #aj ye>s prec$+ 
! date ( enactm5t ( ?is ,act4 ,su* /udy 
%all include--  7#a7 a review ( heal?   
c>e-relat$ legislative1 adm9i/rative1 & 
judicial decisions by (fic]s & employees
 ( ! ,f$]al ,gov]nm5t t h affect$ access
 to pa9 managem5t /rategies ) an        
emphasis on ph>maceuticals2  7#b7 an    
analysis ( :at is kn[n ab\t ! co/s &    

b5efits1 :e!r f9ancial or nonf9ancial1 (
 rev]s+ or revis+ su* decisions         
individually or 9 comb9ation1 includ+   
:e!r ! rev]sals or revisions w\ld be    
expect$ to a*ieve a r$uction 9 abuse (1 
addiction to1 ov]dose on1 & dea? f      
opioids2  7#c7 an analysis ( ! diff]5ces
 among ,/ate-bas$ prescription drug     
monitor+ programs1 includ+ an analysis (
 :at is kn[n ab\t ! effects ( su*       
diff]5ces on monitor+ = abuse (1        
addiction to1 ov]dose on1 & dea? f      
opioids2  7#d7 an analysis ( :at is kn[n
 ab\t positive & negative impacts t     
prescrib+ limitations1 bo? ,/ate &      
,f$]al1 h on pati5t m$ical outcomes1    
includ+ = *ronic pa9 pati5ts2 &  7#e7 an
 analysis ( :at is kn[n ab\t ! co/s &   
b5efits to pay]s ( us+ abuse-det]r5t    
=mulations ( opioid pa9 m$ications1     
comp>$ to opioid pa9 m$ications )\t     
abuse-det]r5t features4